These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 9788568

  • 1. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J, Lejeune F.
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase I trial of temozolomide using an extended continuous oral schedule.
    Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, Roddie M, Glaser M, Brampton MH, Rustin GJ.
    Cancer Res; 1998 Oct 01; 58(19):4363-7. PubMed ID: 9766665
    [Abstract] [Full Text] [Related]

  • 5. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ, Malkin MG, Kleber M, Abrey LE.
    Neuro Oncol; 2004 Jul 01; 6(3):247-52. PubMed ID: 15279717
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
    Grossman R, Tyler B, Rudek MA, Kim E, Zadnik P, Khan U, Blakeley JO, Pathak AP, Brem H.
    Cancer Chemother Pharmacol; 2013 Jul 01; 72(1):93-100. PubMed ID: 23649683
    [Abstract] [Full Text] [Related]

  • 17. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
    Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL.
    Clin Cancer Res; 2001 Aug 01; 7(8):2309-17. PubMed ID: 11489806
    [Abstract] [Full Text] [Related]

  • 18. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
    Tas F, Camlica H, Topuz E.
    Cancer Chemother Pharmacol; 2008 Jul 01; 62(2):293-8. PubMed ID: 17909803
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
    Chang J, Atkinson H, A'Hern R, Lorentzos A, Gore ME.
    Eur J Cancer; 1994 Jul 01; 30A(14):2093-5. PubMed ID: 7857710
    [Abstract] [Full Text] [Related]

  • 20. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
    Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS.
    Neuro Oncol; 2009 Oct 01; 11(5):556-61. PubMed ID: 19289491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.